

## NEWS

Contact:

**Robert W. Scherrer**  
Chief Financial Officer  
Genomas, Inc.  
TEL: 860-545-4570

**FOR IMMEDIATE RELEASE**  
**22 September 2009**



### **Genomas Receives Award as *The Most Promising Life Sciences Company of the Year* Company is Recognized with Connecticut Technology Council's *2009 Innovation Pipeline Awards***

**HARTFORD, CT** – Genomas<sup>®</sup>, a biomedical company advancing DNA-Guided medicine, received the award as *The Most Promising Life Sciences Company of the Year* at the *Innovation & Entrepreneurship Summit* hosted by the Connecticut Center for Advanced Technology (CCAT) and Cantor Colburn LLP in New Haven, CT on 17 September 2009.

In receiving the award, Robert W. Scherrer, Chief Financial Officer stated: “These are extremely exciting times at Genomas as we just celebrated our 5<sup>th</sup> Anniversary. We have recently been awarded our third Phase II SBIR grant for product development, our existing HILOmet PhyziOType™ System to individualize the management of antidepressants has doubled in sales over the last 9 months and we are about to launch a second breakthrough product, the PIMS PhyziOType™ System for the individualized management of antipsychotic medications.”

In presenting the award, Joseph Bronzino, PhD, President of the BEACON Alliance, Hartford, CT, observed: “We have closely followed Genomas and are amazed at their progress as their breakthrough technology for personalized medicine has reached the market. We are pleased to see them grow to a healthcare operating business anchored by their partnership with Hartford Hospital.”

Gualberto Rúaño, M.D., Ph.D., President/CEO of Genomas commented: “We are most thankful to Cantor Colburn and CCAT for this award. It is reassuring and inspiring to witness the recognition of our business model as we pioneer the diversification of the biotechnology industry of Connecticut into healthcare delivery with the State capital as launchpad.”

#### **ABOUT GENOMAS**

Genomas is a biomedical company advancing DNA-Guided Medicine and personalized healthcare. The company develops revolutionary *PhyziOType™* Systems for DNA-guided management and prescription of drugs used to treat heart disease, mental illness, and diabetes. *PhyziOType* Systems are designed to provide physicians with an unprecedented capability to select for each patient the safest and most effective drug treatment to achieve treatment goals and enhance patient compliance. The company's clinical pharmacogenetic tests and consultation service are provided through its Laboratory of Personalized Health (LPH), an accredited and licensed high-complexity molecular diagnostic center. Genomas is located on the campus of Hartford Hospital. Please visit [www.genomas.com](http://www.genomas.com) for more information.

#### **ABOUT THE INNOVATION PIPELINE PROGRAM**

The Innovation Pipeline program is a virtual incubator for tech companies in Connecticut with less than \$5 million in sales that provides a variety of services to tech start-ups, including providing mentors, introductions to angel investors and to professional services firms and a variety of other information and referral services. This program, founded by the Connecticut Technology Council, is managed by the Connecticut Center for Advanced Technology. Please visit [www.ccat.us](http://www.ccat.us) and [www.ctc.org](http://www.ctc.org) for more information.

###